Evidence map›Paper›PMID 36376606›Full record

ReviewPharmaceutical research2023

Nanotechnology-Based Nucleic Acid Vaccines for Treatment of Ovarian Cancer.

Simav Gildiz, Tamara Minko

Open access · hybridAbstract readReview
In one paragraph

Review in Pharmaceutical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Nucleic Acid Delivery.Pharmaceutical research · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Simav GildizDepartment of Pharmaceutics, Rutgers, the State University of New Jersey, Piscataway, NJ, USA.
Tamara MinkoDepartment of Pharmaceutics, Rutgers, the State University of New Jersey, Piscataway, NJ, USA. minko@pharmacy.rutgers.edu.ORCID http://orcid.org/0000-0002-1633-4705
Rutgers, The State University of New Jersey · US

Funding

Nanotechnology-based personalized treatment of metastatic ovarian cancerR01CA269513 · NCI · RUTGERS, THE STATE UNIV OF N.J. · PI Tamara Minko · 2022 to 2026
$3.0M
Bionanotechnology approach for treatment of lung cancerR01CA238871 · NCI · RUTGERS, THE STATE UNIV OF N.J. · PI MINKO, TAMARA · 2019 to 2023
$2.9M
NCI NIH HHS R01 CA238871NCI NIH HHS R01 CA269513NIH HHS R01 CA238871NIH HHS R01 CA269513
6 · The paper itself

Abstract

Anticancer vaccines represent a promising approach for effective treatment of cancer and along with recent advantages of nucleic acid-based vaccines for other diseases form a prospective and potentially efficacious direction of the research, development and clinical applications. Despite the ongoing several clinical trials of mRNA vaccines for the treatment of various types of cancer, to-date no cancer vaccines were approved by the US Food and Drug Administration. The present review analyzes and summarizes major approaches for treating of different forms of ovarian cancer including mRNA-based vaccines as well as nanotechnology-based approaches for their delivery.

Indexed as

Cancer VaccinesNanoparticlesOvarian NeoplasmsVaccinesFemaleHumansNanotechnologyNucleic Acid-Based VaccinesProspective StudiesCancer VaccinesNucleic Acid-Based VaccinesVaccinescancermRNAnanoparticlesovarianvaccine

Identifiers

PMID36376606
PMCPMC9663189
OpenAlexW4308987289

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.